SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biochem Pharma (BCHE)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Del Holmes who wrote (266)4/7/1998 8:38:00 PM
From: Wilfredo Pagani  Read Replies (2) of 783
 
Today the window open for the next ride, The epivir or 3tc had completed its phase 3 trials (two trials) and is expecting aproval for chronic hepatitis B by the FDA this year. This opening will not last too much time. On May 1998 At New Orleans AGA (American Gastroenterology Association) meeting Dr Jules Diengtag will present to medical community the data from this trials,so far it have been well tolerated with few side effects and came in an oral presentation. It will nevertheless require Interferon (current treatment for both hepatitis B and C) to do seroconversion. It appears to improve histology (liver biopsies) and can be use in advance liver damage. Hepatitis B had decrease in in frecuency but in Assian-Americans incidence is very high. So I will get some more in this window sale.WPagani
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News